APSR2026-238

Yes
Late-Breaking
Submitted
Poster Presentation
 
AP12-028
P105
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1216223-46904-APSR2026-238_440121.pdf
Format: PDF Only
16. Interstitial Lung Disease
4

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Ern-Wei Peck * Singapore General Hospital Respiratory Medicine Singapore Singapore
Tertius Tansloan Tuy - Singapore General Hospital Haematology Singapore Singapore
Kendra Jing Ying Tang - Singapore General Hospital Respiratory Medicine Singapore Singapore
Brian Wei Chua Lee - Singapore General Hospital Respiratory Medicine Singapore Singapore
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Ern-Wei
Peck
ernweipeck@gmail.com
+6583110575
Under 30
Singapore
Case Report
An Unusual Case of Idiopathic Pulmonary Syndrome (IPS) with concomitant Human Herpes Virus-6 (HHV-6) Pneumonitis after Allogenic Stem Cell Transplant (SCT)
Maximum 25 words
Abstract Content
 
 
 
 
Pulmonary infiltrates in immunocompromised patients always pose a diagnostic challenge. We report a case of concomitant IPS and HHV-6 pneumonitis 21 days after allogenic SCT.
58-year-old lady with multiple myeloma underwent allogenic SCT. She engrafted on Day 18 post-transplant. She developed rapidly worsening hypoxaemia on Day 29, requiring intubation and mechanical ventilation. Computer Tomography (CT) thorax scan revealed extensive air space consolidation and ground glass opacification (Figure 1). She underwent bronchoalveolar lavage which revealed positive HHV-6 PCR. HHV-6 was also detected in blood at 9690 copies/ml. Given her clinical tempo and concerns for concomitant IPS, Intravenous (IV) Foscarnet and IV Hydrocortisone was started. Decision was made to escalate immunosuppression after 12 days due to lack of clinical improvement. IV Methylprednisolone and Subcutaneous (SC) Etanercept was started, with the addition of Per Os (PO) Ruxolitinib subsequently. There was significant clinical improvement and she was extubated to non-invasive ventilation (NIV) on Day 17 of Intensive Care Unit (ICU) admission.
IPS is an acute non-infectious diffuse lung injury that occurs after allogenic SCT. Studies estimate 4 to 12% incidence rate with 1-year mortality rate of up to 70% despite treatment (Wenger D S et al, Biology of Blood and Marrow Transplant, 2019, 26(2), 413-420). Pathogenesis is suggested to involve myeloablative conditioning leading to alloimmune cytokine storm, lung recruitment of inflammatory cells and release of oxidants. Whilst IPS is mainly a diagnosis of exclusion, it is not uncommon for immunocompromised patients to have concomitant infections. Treatment is primarily supportive with immunosuppressive therapy (IST). Newer evidence may suggest a potential therapeutic benefit of Ruxolitinib in addition to standard of care IST (Shahzad M et al, Transplant Immunology, 2024, 87, 102135); however, larger studies are needed to investigate this.
 
 
Yes
Yes
https://storage.unitedwebnetwork.com/files/1285/1216223-37089-Figure1_373844.png
JPG or JPEG or PNG format ONLY
Idiopathic pneumonia syndrome (IPS), Pneumonitis, Pneumonia
maximum 3 keywords and no abbreviations, separated by commas
There are no conflicts of interest to declare.
285